The purpose of this study is to evaluate the safety and efficacy of Melphalan and BUCY+VP-16 myeloablative conditioning regimens in multiple myeloma undergoing autologous hematopoietic stem cell transplantation.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
122
Busulfan was administered at 3.2 mg/kg/day on days -8 to -6. -7 to -4.
Cyclophosphamide was administered at 60 mg/kg/day on days -5 to -4. on days -3 to -2.
Etoposide was administered at 10 mg/kg/day on days -3 to -2. -3 to -2.
Department of Hematology,Nanfang Hospital, Southern Medical University
Guangzhou, Guangdong, China
RECRUITINGOS
overall survival (OS)
Time frame: 3 year
relapse rate relapse rate
relapse rate
Time frame: 3 year
DFS
disease-free survival (DFS)
Time frame: 3 year
TRM
transplant-related mortality (TRM)
Time frame: 3 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Melphalan was administered at 200mg/m2 on day -2.